Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 2.89 per share from $ 19.35 million in revenue.
For the full year, analysts predict revenues of $ 60.13 million, while looking forward to loss of $ 11.97 per share.
Previous Quarter Performance
Biohaven Pharmaceutical Holding Company Ltd. reported loss for the second quarter of $ 2.55 per share, from the revenue of $ 9.70 million. Wall street analysts are predicting, BHVN to report 2Q20 loss of $ 2.61 per share from revenue of $ 7.65 million. The bottom line results beat street analysts by $ 0.06 or 2.30 percent, at the same time, top line results outshined analysts by $ 2.05 million or 26.80 percent.
Stock Performance
On Friday, shares of Biohaven Pharmaceutical Holding Company Ltd. has traded high as $ 87.91 and has cracked $ 83.51 on the downward trend, reaching $ 84.31 with volume of 772.90 thousand shares.
According to the previous trading day, closing price of $ 84.31, representing a 230.76 % increase from the 52 week low of $ 26.56 and a 1.8 % decrease over the 52 week high of $ 89.46.
The company has a market capital of $ 5.03 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 63.00 target price.
Conference Call
Biohaven Pharmaceutical Holding Company Ltd. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biohavenpharma.com
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation.
